- Market Capitalization, $K 105,468,944
- Shares Outstanding, K 2,692,595
- Annual Sales, $ 43,783 M
- Annual Income, $ 7,382 M
- 60-Month Beta 0.71
- Price/Sales 2.38
- Price/Cash Flow 9.98
- Price/Book 3.45
|Period||Period Low||Period High||Performance|
| || |
+0.61 (+1.57%)since 09/20/21
| || |
+0.37 (+0.95%)since 07/20/21
| || |
+3.42 (+9.49%)since 10/20/20
As the FDA moves to approve multiple booster shots for all of the available Covid-19 vaccines available ...
Gilead (GILD) wins FDA approval for the label expansion of HIV treatment Biktarvy for the pediatric patient population.
Because the inflationary environment and supply chain constraints could keep the overall stock market under pressure in the near term, we think it could be wise to bet on quality dividend stocks to benefit...
Gilead's (GILD) application for breast cancer drug gets positive opinion for approval from EMA's CHMP.
GSK vs. NVO: Which Stock Is the Better Value Option?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...
/PRNewswire/ -- USA News Group - As vaccine passport programs continue to roll out in new markets across the globe, especially in Europe and North America, it...
VANCOUVER – Biotech Today – As vaccine passport programs continue to roll out in new markets ...
|Glaxosmithkline Plc ADR|
|Vaneck Pharmaceutical ETF|
|Pacer Biothreat Strategy ETF|
|Pacer Global Cash Cows Dividend ETF|
|Pacer Military Times Best Employers ETF|
|Alps Hillman Active Value ETF|
|3rd Resistance Point||40.00|
|2nd Resistance Point||39.77|
|1st Resistance Point||39.62|
|1st Support Level||39.23|
|2nd Support Level||39.00|
|3rd Support Level||38.85|